290 related articles for article (PubMed ID: 20524815)
1. Iron chelation therapy in hereditary hemochromatosis and thalassemia intermedia: regulatory and non regulatory mechanisms of increased iron absorption.
Kontoghiorghes GJ; Spyrou A; Kolnagou A
Hemoglobin; 2010 Jun; 34(3):251-64. PubMed ID: 20524815
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with non-transfusion-dependent thalassemia syndromes.
Kontoghiorghe CN; Kontoghiorghes GJ
Drug Des Devel Ther; 2016; 10():465-81. PubMed ID: 26893541
[TBL] [Abstract][Full Text] [Related]
3. Iron chelation therapy in hereditary hemochromatosis and thalassemia intermedia: regulatory and non regulatory mechanisms of increased iron absorption [Kontoghiorghes GJ, Spyrou A, Kolganou A. Hemoglobin. 2010;34(3); 251-264].
Nick HP
Hemoglobin; 2011; 35(2):175-9. PubMed ID: 21417578
[No Abstract] [Full Text] [Related]
4. Future chelation monotherapy and combination therapy strategies in thalassemia and other conditions. comparison of deferiprone, deferoxamine, ICL670, GT56-252, L1NAll and starch deferoxamine polymers.
Kontoghiorghes GJ
Hemoglobin; 2006; 30(2):329-47. PubMed ID: 16798657
[TBL] [Abstract][Full Text] [Related]
5. A new era in iron chelation therapy: the design of optimal, individually adjusted iron chelation therapies for the complete removal of iron overload in thalassemia and other chronically transfused patients.
Kontoghiorghes GJ
Hemoglobin; 2009; 33(5):332-8. PubMed ID: 19814679
[TBL] [Abstract][Full Text] [Related]
6. Ethical issues and risk/benefit assessment of iron chelation therapy: advances with deferiprone/deferoxamine combinations and concerns about the safety, efficacy and costs of deferasirox.
Kontoghiorghes GJ
Hemoglobin; 2008; 32(1-2):1-15. PubMed ID: 18274978
[TBL] [Abstract][Full Text] [Related]
7. Incidence of hepatocellular carcinoma in a thalassemia unit.
Fragatou S; Tsourveloudis I; Manesis G
Hemoglobin; 2010 Jun; 34(3):221-6. PubMed ID: 20524812
[TBL] [Abstract][Full Text] [Related]
8. Risk/benefit assessment, advantages over other drugs and targeting methods in the use of deferiprone as a pharmaceutical antioxidant in iron loading and non iron loading conditions.
Kontoghiorghes GJ; Efstathiou A; Kleanthous M; Michaelides Y; Kolnagou A
Hemoglobin; 2009; 33(5):386-97. PubMed ID: 19814684
[TBL] [Abstract][Full Text] [Related]
9. Advances in iron overload therapies. prospects for effective use of deferiprone (L1), deferoxamine, the new experimental chelators ICL670, GT56-252, L1NA11 and their combinations.
Kontoghiorghes GJ; Eracleous E; Economides C; Kolnagou A
Curr Med Chem; 2005; 12(23):2663-81. PubMed ID: 16305464
[TBL] [Abstract][Full Text] [Related]
10. Iron mobilization from transferrin and non-transferrin-bound-iron by deferiprone. Implications in the treatment of thalassemia, anemia of chronic disease, cancer and other conditions.
Kontoghiorghes GJ
Hemoglobin; 2006; 30(2):183-200. PubMed ID: 16798643
[TBL] [Abstract][Full Text] [Related]
11. Iron chelation therapy for patients with myelodysplastic syndrome.
Yeh SP; Yang YS; Yao CY; Peng CT
Hemoglobin; 2009; 33(5):339-45. PubMed ID: 19814680
[TBL] [Abstract][Full Text] [Related]
12. A new approach for potential combined chelation therapy using mono- and bis-hydroxypyridinones.
Santos MA; Gama S; Gil M; Gano L
Hemoglobin; 2008; 32(1-2):147-56. PubMed ID: 18274992
[TBL] [Abstract][Full Text] [Related]
13. The proceedings of the 17th International Conference on Chelation: application of effective chelation therapies in iron loading and non iron loading conditions, and the gap in the prevention and treatment policies on thalassemia between developed and developing countries.
Kontoghiorghes GJ
Hemoglobin; 2009; 33(5):283-6. PubMed ID: 19814673
[TBL] [Abstract][Full Text] [Related]
14. Oral iron chelation with 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in iron loaded thalassemia patients.
Olivieri NF; Matsui D; Liu PP; Blendis L; Cameron R; McClelland RA; Templeton DM; Koren G
Bone Marrow Transplant; 1993; 12 Suppl 1():9-11. PubMed ID: 8374574
[TBL] [Abstract][Full Text] [Related]
15. Treatment of iron overload in thalassemia.
Cianciulli P
Pediatr Endocrinol Rev; 2008 Oct; 6 Suppl 1():208-13. PubMed ID: 19337180
[TBL] [Abstract][Full Text] [Related]
16. Current recommendations for chelation for transfusion-dependent thalassemia.
Kwiatkowski JL
Ann N Y Acad Sci; 2016 Mar; 1368(1):107-14. PubMed ID: 27186943
[TBL] [Abstract][Full Text] [Related]
17. The role of iron and chelators on infections in iron overload and non iron loaded conditions: prospects for the design of new antimicrobial therapies.
Kontoghiorghes GJ; Kolnagou A; Skiada A; Petrikkos G
Hemoglobin; 2010 Jun; 34(3):227-39. PubMed ID: 20524813
[TBL] [Abstract][Full Text] [Related]
18. Thalassemia.
Cohen AR; Galanello R; Pennell DJ; Cunningham MJ; Vichinsky E
Hematology Am Soc Hematol Educ Program; 2004; ():14-34. PubMed ID: 15561674
[TBL] [Abstract][Full Text] [Related]
19. Outcomes, utilization, and costs among thalassemia and sickle cell disease patients receiving deferoxamine therapy in the United States.
Delea TE; Hagiwara M; Thomas SK; Baladi JF; Phatak PD; Coates TD
Am J Hematol; 2008 Apr; 83(4):263-70. PubMed ID: 17924547
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of 1-2, dimethyl-3-hydroxypyrid-4-one (L1) as an oral iron chelator in patients of beta thalassaemia major with iron overload.
Agarwal MB; Gupte SS; Vasandani D; Viswanathan C; Puniyani RR; Ramanathan J; Massil DE; Shah S; Rajyadhyaksha GC; Bhave AA
J Assoc Physicians India; 1991 Sep; 39(9):669-72. PubMed ID: 1814897
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
